Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Black Hawk Acquisition Corporation Class A Ordinary Shares

BKHA

Black Hawk Acquisition Corp is a Blank check company.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $6.09 – $8.07
Volume 35,219
Market cap $30M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for BKHA.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for BKHA.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer

Vesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership change comes as Vesicor prepares to complete its proposed de-SPAC merger with Black Hawk Acquisition Corporation and accelerate IND-enabling studies with an FDA submission targeted for 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.